Review: Glycation of human serum albumin

Clinica Chimica Acta

Volumn 425, Issue , 2013, Pages 64-76

  Anguizola, Jeanethe ^a   Matsuda, Ryan ^a   Barnaby, Omar S ^a   Hoy, K S ^a   Wa, Chunling ^a   DeBolt, Erin ^a   Koke, Michelle ^a   Hage, David S ^a  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

Diabetes; Drug protein binding; Glycated albumin; Glycation; Human serum albumin; Protein modification

Indexed keywords

ADVANCED GLYCATION END PRODUCT; FATTY ACID; HUMAN SERUM ALBUMIN; SULFONYLUREA DERIVATIVE; WARFARIN;

BINDING AFFINITY; DIABETES MELLITUS; DRUG PROTEIN BINDING; GLYCEMIC CONTROL; HUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN MODIFICATION; PROTEIN STRUCTURE; REVIEW; STRUCTURE ANALYSIS; THERMODYNAMICS;

DIABETES; DRUG-PROTEIN BINDING; GLYCATED ALBUMIN; GLYCATION; HUMAN SERUM ALBUMIN; PROTEIN MODIFICATION;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS; FATTY ACIDS; GLYBURIDE; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPOGLYCEMIC AGENTS; KINETICS; MODELS, MOLECULAR; PROTEIN BINDING; SERUM ALBUMIN; SULFONYLUREA COMPOUNDS; THERMODYNAMICS;

EID: 84883634135     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.07.013     Document Type: Review

References (145)

1. International Diabetes Federation diabetes atlas 2011, International Diabetes Federation, Brussels, Belgium. 5th ed.
2. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2011 2011, U.S. Centers for Disease Control, Atlanta, GA.
3. Lehninger principles of biochemistry 2005, W. H. Freeman and Company, New York. D.L. Nelson, M.M. Cox (Eds.).
4. Hartog J.W.L., Voors A.A., Bakker S.J.L., Smit A.J., Veldhuisen D.J.V. Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur J Heart Fail 2007, 9:1146-1155.
5. Olijhoeka J.K., Graafb Y.V.D., Bangaa J.D., Algrab A., Rabelinka T.J., Visserena F.L.J. The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 2004, 25:342-348.
6. Perneger T.V., Brancati F.L., Whelton P.K., Klag M.J. End-stage renal disease attributable to diabetes mellitus. Ann Intern Med 1994, 121:912-918.
7. Turk Z., Misur I., Turk N. Temporal association between lens protein glycation and cataract development in diabetic rats. Acta Diabetol 1997, 34:49-54.
8. Bild D.E., Selby J.V., Sinnock P., Browner W.S., Braveman P., Showstack J.A. Lower-extremity amputation in people with diabetes. Epidemiology and prevention. Diabetes Care 1989, 12:24-31.
9. Thornalley P.J., Langborg A., Minhas H.S. Formation of glyoxal, methylglyoxal and 3-deoxyglucosone in the glycation of proteins by glucose. Biochem J 1999, 344:109-116.
10. Maillard L.C. Action des acides amines sur les sucres: formation des melanoidines par voie methodique. C R Acad Sci 1912, 154:66-68.
11. Nursten H. The Maillard reaction 2005, Royal Society of Chemistry, Cambridge, UK.
12. Lapolla A., Fedele D., Reitano R., et al. Mass spectrometric study of in vivo production of advanced glycation end-products/peptides. J Mass Spectrom 2005, 40:969-972.
13. Lapolla A., Fedele D., Seraglia R., Traldi P. The role of mass spectrometry in the study of non-enzymatic protein glycation in diabetes: an update. Mass Spectrom Rev 2006, 25:775-797.
14. Zhang Q., Ames J.M., Smith R.D., Baynes J.W., Metz T.O. A perspective on the Maillard reaction and the analysis of protein glycation by mass spectrometry: probing the pathogenesis of chronic disease. J Proteome Res 2009, 8:754-769.
15. Baynes J.W., Thorpe S.R., Murtiashaw M.H. Nonenzymatic glucosylation of lysine residues in albumin. Methods Enzymol 1984, 106:88-98.
16. Perejda A., Uitto J. Nonenzymatic glycosylation of collagen and other proteins: relationship to development of diabetic complications. Coll Relat Res 1982, 2:81-88.
17. Rogozinski S., Blumenfeld O., Seifter S. The nonenzymatic glycosylation of collagen. Arch Biochem Biophys 1983, 221:428-437.
18. Jones R.L., Cerami A. Nonenzymatic glycosylation of proteins in diabetes mellitus. Recent Adv Diabetes 1984, 1:173-180.
19. Peters T. All about albumin: biochemistry, genetics, and medical applications 1996, Academic Press, San Diego.
20. Textbook of clinical chemistry 1986, Philadelphia, Saunders. N.W. Tietz (Ed.).
21. Colmenarejo G. In silico prediction of drug-binding strengths to human serum albumin. Med Res Rev 2003, 23:275-301.
22. Dockal M., Carter D.C., Ruker F. The three recombinant domains of human serum albumin. J Biol Chem 1999, 274:29303-29310.
23. He X.M., Carter D.C. Atomic structure and chemistry of human serum albumin. Nature 1992, 358:209-215.
24. Otagiri M. A molecular functional study on the interactions of drugs with plasma proteins. Drug Metab Pharmacokinet 2005, 20:309-323.
25. Choi E.J., Foster M.D. The role of specific binding in human serum albumin adsorption to self-assembled monolayers. Langmuir 2002, 18:557-561.
26. Shaklai N., Garlick R.L., Bunn H.F. Nonenzymatic glycosylation of human serum albumin alters its conformation and function. J Biol Chem 1984, 259:3812-3817.
27. Curry S., Mandelkow H., Brick P., Franks N. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat Struct Biol 1998, 5:827-835.
28. Koyama H., Sugioka N., Uno A., Mori S., Nakajima K. Effects of glycosylation of hypoglycemic drug binding to serum albumin. Biopharm Drug Dispos 1997, 18:791-801.
29. Ascoli G.A., Domenici E., Bertucci C. Drug binding to human serum albumin: abridged review of results obtained with high-performance liquid chromatography and circular dichroism. Chirality 2006, 18:667-679.
30. Simard J.R., Zunszain P.A., Ha C.E., et al. Locating high-affinity fatty acid-binding sites on albumin by X-ray crystallography and NMR spectroscopy. Proc Natl Acad Sci U S A 2005, 102:17958-17963.
31. Sudlow G., Birkett D.J., Wade D.N. Characterization of two specific drug binding sites on human serum albumin. Mol Pharmacol 1975, 11:824-832.
32. Sudlow G., Birkett D.J., Wade D.N. Further characterization of specific drug binding sites on human serum albumin. Mol Pharmacol 1976, 12:1052-1061.
33. Sengupta A., Hage D.S. Characterization of the binding of digitoxin and acetyldigitoxin to human serum albumin by high-performance affinity chromatography. J Chromatogr B 1999, 725:91-100.
34. Hage D.S., Sengupta A. Studies of protein binding to non-polar solutes by using zonal elution and high-performance affinity chromatography: interactions of cis- and trans-clomiphene with human serum albumin in the presence of β-cyclodextrin. Anal Chem 1998, 70:4602-4609.
35. Loun B., Hage D.S. Chiral separation mechanisms in protein-based HPLC columns. I. Thermodynamic studies of R- and S-warfarin binding to immobilized human serum albumin. Anal Chem 1994, 66:3814-3822.
36. Yang J., Hage D.S. Characterization of the binding and chiral separation of d- and l-tryptophan on a high-performance immobilized human serum albumin column. J Chromatogr 1993, 645:241-250.
37. Cohen M. Measurement of circulating glycated proteins to monitor intermediate-term changes in glycaemic control. Eur J Clin Chem Clin Biochem 1992, 30:851-859.
38. Roohk H.V., Zaidi A.R. A review of glycated albumin as an intermediate glycation index for controlling diabetes. J Diabetes Sci Technol 2008, 2:1114-1121.
39. Guerin-Dubourg A., Catan A., Bourdon E., Rondeau P. Structural modifications of human albumin in diabetes. Diabetes Metab 2012, 38:171-178.
40. Bry L., Chen P.C., Sacks D.B. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem 2001, 47:153-163.
41. Zheng C.M., Ma W.Y., Wu C.C., Lu K.C. Glycated albumin in diabetic patients with chronic kidney disease. Clin Chim Acta 2012, 413:1555-1561.
42. Cohen R.M., Sacks D.B. Comparing multiple measures of glycemia: how to transition from biomarker to diagnostic test?. Clin Chem 2012, 58:1615-1617.
43. Lee E.Y., Lee B.W., Kim D., et al. Glycated albumin is a useful glycation index for monitoring fluctuating and poorly controlled type 2 diabetes patients. Acta Diabetol 2011, 48:167-172.
44. Mehrotra R., Kalantar-Zadeh K., Adler S. Assessment of glycemic control in dialysis patients: glycosylated hemoglobin or glycated albumin?. Clin J Am Soc Nephrol 2011, 6:1520-1522.
45. Armbruster D.A. Fructosamine: structure, analysis, and clinical usefulness. Clin Chem 1987, 33:2153-2163.
46. Mashiba S., Uchida K., Okuda S., Tomita S. Measurement of glycated albumin by the nitroblue tetrazolium colorimetric method. Clin Chim Acta 1992, 212:3-15.
47. Kobayashi K., Yoshimoto K., Hirauchi K., Uchida K. A novel colorimetric method for determination of glycated protein based on 2-keto-glucose release with hydrazine. Biol Pharm Bull 1993, 16:195-198.
48. Baker J.R., Zyzak D.V., Thorpe S.R., Baynes J.W. Chemistry of the fructosamine assay: d-glucosone is the product of oxidation of Amadori compounds. Clin Chem 1994, 40:1950-1955.
49. Yatscoff R.W., Tevaarwerk G.J., MacDonald J.C. Quantification of nonenzymically glycated albumin and total serum protein by affinity chromatography. Clin Chem 1984, 30:446-449.
50. Uchida T., Kozuma T., Yasukawa K., Shima K. Glycated albumin analyzer. Methods Chromatogr 1996, 1:33-41.
51. Poduslo J.F., Curran G.L. Increased permeability across the blood-nerve barrier of albumin glycated in vitro and in vivo from patients with diabetic polyneuropathy. Proc Natl Acad Sci U S A 1992, 89:2218-2222.
52. Yasukawa K., Abe F., Shida N., et al. High-performance affinity chromatography system for the rapid, efficient assay of glycated albumin. J Chromatogr 1992, 597:271-275.
53. Hage D.S., Anguizola J.A., Bi C., et al. Pharmaceutical and biomedical applications of affinity chromatography: recent trends and developments. J Pharm Biomed Anal 2012, 69:93-105.
54. Hage D.S. Affinity chromatography: a review of clinical applications. Clin Chem 1999, 45:593-615.
55. Cohen M.P., Clements R.S. Measuring glycated proteins: clinical and methodological aspects. Diabetes Technol Ther 1999, 1:57-69.
56. Cohen M.P., Hud E. Measurement of plasma glycoalbumin levels with a monoclonal antibody based ELISA. J Immunol Methods 1989, 122:279-283.
57. Ikeda K., Sakamoto Y., Kawasaki Y., et al. Determination of glycated albumin by enzyme-linked boronate immunoassay (ELBIA). Clin Chem 1998, 44:256-263.
58. Paroni R., Ceriotti F., Galanello R., et al. Performance characteristics and clinical utility of an enzymatic method for the measurement of glycated albumin in plasma. Clin Biochem 2007, 40:1398-1405.
59. Kohzuma T., Koga M. Lucica GA-L glycated albumin assay kit. A new diagnostic test for diabetes mellitus. Mol Diagn Ther 2010, 14:49-51.
60. Kouzuma T., Usami T., Yamakoshi M., Takahashi M., Imamura S. An enzymatic method for the measurement of glycated albumin in biological samples. Clin Chim Acta 2002, 324:61-71.
61. Wang Y., Dou C., Yuan C., Datta A. Development of an automated enzymatic assay for the determination of glycated serum protein in human serum. Clin Chem 2005, 51:1991-1992.
62. Zhang Q., Tang N., Schepmoes A.A., Phillips L.S., Smith R.D., Metz T.O. Proteomic profiling of nonenzymatically glycated proteins in human plasma and erythrocyte membranes. J Proteome Res 2008, 7:2025-2032.
63. Dingari N.C., Horowitz G.L., Kang J.W., Dasari R.R., Barman I. Raman spectroscopy provides a powerful diagnostic tool for accurate determination of albumin glycation. PLoS One 2012, 7:e32406.
64. Zhernovaya O.S., Tuchin V.V., Meglinski I.V. Monitoring of blood proteins glycation by refractive index and spectral measurements. Laser Phys Lett 2008, 5:460-464.
65. Hinton D.J.S., Ames J.M. Analysis of glycated protein by capillary electrophoresis. Int Congress Ser 2002, 1245:471-474.
66. Pereira Morais M.P., Mackay J.D., Bhamra S.K., et al. Analysis of protein glycation using phenylboronate acrylamide gel electrophoresis. Proteomics 2010, 10:48-58.
67. Martin G.J., Rand J.S., Hickey S.A. Separation of serum glycated proteins by agarose gel electrophoresis and nitroblue tetrazolium staining in diabetic and normal cats. Vet Clin Pathol 2006, 35:307-310.
68. Thornalley P.J. Dicarbonyl intermediates in the Maillard reaction. Ann N Y Acad Sci 2005, 1043:111-117.
69. Mendez D.L., Jensen R.A., McElroy L.A., Pena J.M., Esquerra R.M. The effect of non-enzymatic glycation on the unfolding of human serum albumin. Arch Biochem Biophys 2005, 444:92-99.
70. Fitzpatrick G., Duggan P.F. The effect of non-enzymatic glycation on ligand binding to human serum albumin. Biochem Soc Trans 1987, 15:267-268.
71. Nakajou K., Watanabe H., Kragh-Hansen U., Maruyama T., Otagiri M. The effect of glycation on the structure, function and biological fate of human serum albumin as revealed by recombinant mutants. Biochim Biophys Acta 2003, 1623:88-97.
72. Joseph K.S., Anguizola J., Jackson A.J., Hage D.S. Chromatographic analysis of acetohexamide binding to glycated human serum albumin. J Chromatogr B 2010, 878:2775-2781.
73. Joseph K.S., Anguizola J., Hage D.S. Binding of tolbutamide to glycated human serum albumin. J Pharm Biomed Anal 2011, 54:426-432.
74. Joseph K.S., Hage D.S. The effects of glycation on the binding of human serum albumin to warfarin and l-tryptophan. J Pharm Biomed Anal 2010, 53:811-818.
75. Matsuda R., Anguizola J., Joseph K.S., Hage D.S. High-performance affinity chromatography and the analysis of drug interactions with modified proteins: binding of gliclazide with glycated human serum albumin. Anal Bioanal Chem 2011, 401:2811-2819.
76. Garlick R.L., Mazer J.S. The principal site of nonenzymatic glycosylation of human serum albumin in vivo. J Biol Chem 1983, 258:6142-6146.
77. Day J.F., Thorpe S.F., Baynes J.W. Nonenzymatically glycosylated albumin. J Biol Chem 1979, 254:595-597.
78. Iberg N., Fluckiger R. Nonenzymatic glycosylation of albumin in vivo: identification of multiple glycosylated sites. J Biol Chem 1986, 261:13542-13545.
79. Arif B., Jalaluddin M., Moinuddin A., Ahmad J., Arif Z., Alam K. Structural and immunological characterization of Amadori-rich human serum albumin: role in diabetes mellitus. Arch Biochem Biophys 2012, 522:17-25.
80. Zoellner H., Hou J.Y., Hochgrebe T., et al. Fluorometric and mass spectrometric analysis of nonenzymatic glycosylated albumin. Biochem Biophys Res Commun 2001, 284:83-89.
81. Westwood M.E., Thornalley P.J. Molecular characteristics of methylglyoxal-modified bovine and human serum albumins. Comparison with glucose-derived advanced glycation endproduct-modified serum albumins. J Protein Chem 1995, 14:359-372.
82. Barzegar A., Moosavi-Movahedi A.A., Sattarahmady N., et al. Spectroscopic studies of the effects of glycation of human serum albumin on l-trp binding. Prot Pep Lett 2007, 14:13-18.
83. Okabe N., Hashizume N. Drug binding properties of glycosylated human serum albumin as measured by fluorescence and circular dichroism. Biol Pharm Bull 1994, 17:16-21.
84. Howard M.J., Smales C.M. NMR analysis of synthetic human serum albumin α-helix 28 identifies structural distortion upon Amadori modification. J Biol Chem 2005, 280:22582-22589.
85. Taneda S., Monnier V.M. ELISA of pentosidine, an advanced glycation endproduct, in biological specimens. Clin Chem 1994, 40:1766-1773.
86. Lee C., Yim M.B., Chock P.B., Yim Y.S., Kang S.O. Oxidation-reduction properties of methylglyoxal-modified protein in relation to free radical generation. J Biol Chem 1998, 273:25272-25278.
87. Schleicher E., Wieland O.H. Specific quantitation by HPLC of protein (lysine) bound glucose in human serum albumin and other glycosylated proteins. J Clin Chem Clin Biochem 1981, 19:81-87.
88. ε-(1-carboxyethyl)lysine-modified albumin. Biochem J 2002, 364:1-14.
89. Ahmed N., Thornalley P.J. Chromatographic assay of glycation adducts in human serum albumin glycated in vitro by derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and intrinsic fluorescence. Biochem J 2002, 364:15-24.
90. Lui X., Scouten W.H. Handbook of affinity chromatography 2006, CRC Press, Boca Raton, FL, [Chap 8.]. D.S. Hage (Ed.).
91. Zhang Q., Monroe M.E., Schepmoes A.A., et al. Comprehensive identification of glycated peptides and their glycation motifs in plasma and erythrocytes of control and diabetic subjects. J Proteome Res 2011, 10:3076-3088.
92. Frolov A., Hoffman R. Analysis of Amadori peptides enriched by boronic acid affinity chromatography. Ann N Y Acad Sci 2008, 1126:253-256.
93. Frolov A., Hoffmann R. Identification and relative quantification of specific glycation sites in human serum albumin. Anal Bioanal Chem 2010, 397:2349-2356.
94. Gadgil H.S., Bondarenko P.V., Treuheit M.J., Ren D. Screening and sequencing of glycated proteins by neutral loss scan LC/MS/MS method. Anal Chem 2007, 79:5991-5999.
95. Kisugi R., Kouzuma T., Yamamoto T., et al. Structural and glycation site changes of albumin in diabetic patient with very high glycated albumin. Clin Chim Acta 2007, 382:59-64.
96. Lapolla A., Fedele D., Reitano R., Arico N.C. Enzymatic digestion and mass spectrometry in the studies of advanced glycation end products/peptides. J Am Soc Mass Spectrom 2004, 15:496-509.
97. 13C-reducing sugars for quantitative analysis of glycated proteins in human plasma. Mol Cell Proteomics 2010, 9:579-597.
98. Frost L., Chaudhry M., Bell T., Cohenford M. In vitro galactation of human serum albumin: analysis of the protein's galactation sites by mass spectrometry. Anal Biochem 2011, 410:248-256.
99. Ahmed N., Thornalley P.J. Peptide mapping of human serum albumin modified by methylglyoxal in vitro and in vivo. Ann N Y Acad Sci 2005, 1043:260-266.
100. Ahmed N., Dobler D., Dean M., Thornalley P.J. Peptide mapping identifies hotspot site of modification in human serum albumin by methylglyoxal involved in ligand binding and esterase activity. J Biol Chem 2005, 280:5724-5732.
101. Stefanowicz P., Kijewska M., Kluczyk A., Szewczuk Z. Detection of glycation sites in proteins by high-resolution mass spectrometry combined with isotopic labeling. Anal Biochem 2010, 400:237-243.
102. Brancia F.L., Bereszczak J.Z., Lapolla A., et al. Comprehensive analysis of glycated human serum albumin tryptic peptides by off-line liquid chromatography followed by MALDI analysis on a time-of-flight/curved field reflectron tandem mass spectrometer. J Mass Spectrom 2006, 41:1179-1185.
103. Marotta E., Lapolla A., Fedelle D., et al. Accurate mass measurements by Fourier transform mass spectrometry in the study of advanced glycation end products/peptides. J Mass Spectrom 2003, 38:196-205.
104. Robb D.A., Olufemi O.S., Williams D.A., Midgley J.M. Identification of glycation at the N-terminus of albumin by gas chromatography-mass spectrometry. Biochem J 1986, 261:871-878.
105. 18O labeling and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chim Acta 2010, 411:1102-1110.
106. Barnaby O.S., Cerny R.L., Clarke W., Hage D.S. Comparison of modification sites formed on human serum albumin at various stages of glycation. Clin Chim Acta 2011, 412:277-285.
107. Wa C., Cerny R.L., Clarke W.A., Hage D.S. Characterization of glycation adducts on human serum albumin by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Clin Chim Acta 2007, 385:48-60.
108. 18O-labeling and MALDI-TOF MS. Clin Chim Acta 2011, 412:1606-1615.
109. Lee B.S., Krishnanchettiar S., Lateef S.S., Gupta S. Analyses of the in vitro non-enzymatic glycation of peptides/proteins by matrix-assisted laser desorption/ionization mass spectrometry. Int J Mass Spectrom 2007, 260:67-74.
110. Anguizola J., Joseph K.S., Barnaby O.S., et al. Development of affinity microcolumns for drug-protein binding studies in personalized medicine: interactions of sulfonylurea drugs with in vivo glycated human serum albumin. Anal Chem 2013, 85:4453-4460.
111. Thornalley P.J., Argirova M., Ahmed N., Mann V.M., Argirov O., Dawnay A. Mass spectrometric monitoring of albumin in uremia. Kidney Int 2000, 58:2228-2234.
112. Kato H., Hayase F., Shin D.B., Oimomi M., Baba S. 3-Deoxyglucosone, an intermediate product of the Maillard reaction. Prog Clin Biol Res 1989, 304:69-84.
113. Stitt A.W., Curtis T.M. Advanced glycation and retinal pathology during diabetes. Pharmacol Rep 2005, 57:156-168.
114. Takeuchi M., Kikuchi S., Sasaki N., et al. Involvement of advanced glycation end-products (AGEs) in Alzheimer's disease. Curr Alzheimer Res 2004, 1:39-46.
115. Ulrich P., Cerami A. Protein glycation, diabetes, and aging. Recent Prog Horm Res 2001, 56:1-21.
116. Thornalley P.J. Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems - role in ageing and disease. Drug Metabol Drug Interact 2008, 23:125-150.
117. Thornalley P.J. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 2003, 375:581-592.
118. Singh R., Barden A., Mori T., Beilin L. Advanced glycation end products: a review. Diabetologia 2001, 44:129-146.
119. Baraka-Vidot J., Guerin-Dubourg A., Bourdon E., Rondeau P. Impaired drug-binding capacities of in vitro and in vivo glycated albumin. Biochimie 2012, 94:1960-1967.
120. Voziyan P.A., Khalifah R.G., Thibaudeau C., et al. Modification of proteins in vitro by physiological levels of glucose. J Biol Chem 2003, 278:46616-46624.
121. Syrovy I. Glycation of albumin: reaction with glucose, fructose, galactose, ribose or glyceraldehydes measured using four methods. J Biochem Biophys Methods 1994, 28:115-121.
122. Mereish K.A., Rosenberg H., Cobby J. Glucosylated albumin and its influence on salicylate binding. J Pharm Sci 1982, 1:235-238.
123. Gatti G., Crema F., Attardo-Parrinello G., Fratino P., Aguzzi F., Perucca E. Serum protein binding of phenytoin and valproic acid in insulin-dependent diabetes mellitus. Ther Drug Monit 1987, 9:389-391.
124. McNamara P.J., Blouin R.A., Brazzell R.K. The protein binding of phenytoin, propranolol, diazepam and AL01576 (an aldose reductase inhibitor) in human and rat diabetic serum. Pharm Res 1988, 5:261-265.
125. Ruiz-Cabello F., Erill S. Abnormal serum protein binding of acidic drugs in diabetes mellitus. Clin Pharmacol Ther 1984, 36:691-695.
126. Jackson A.J., Anguizola J., Pfaunmiller E.L., Hage D.S. Use of entrapment and high-performance affinity chromatography to compare the binding of drugs and site-specific probes with normal and glycated human serum albumin. Anal Bioanal Chem 2013, 405:5833-5841.
127. Joseph K.S., Hage D.S. Characterization of the binding of sulfonylurea drugs to HSA by high-performance affinity chromatography. J Chromatogr B 2010, 878:1590-1598.
128. Matsuda R., Anguizola J., Joseph K.S., Hage D.S. Analysis of drug interactions with modified proteins by high-performance affinity chromatography: binding of glibenclamide to normal and glycated human serum albumin. J Chromatogr A 2012, 1265:114-122.
129. Tsuchiya S., Tamiko S., Sekiguchi S. Nonenzymatic glucosylation of human serum albumin and its influence on binding capacity of sulfonylurea drugs. Biochem Pharmacol 1984, 33:2967-2971.
130. Koizumi K., Ikeda C., Ito M., et al. Influence of glycosylation on the drug binding of human serum albumin. Biomed Chromatogr 1998, 12:203-210.
131. Doucet J., Fresel J., Hue G., Moore N. Protein binding of digitoxin, valproate and phenytoin in sera from diabetics. Eur J Clin Pharmacol 1993, 45:577-579.
132. Bohney J.P., Feldhoff R.C. Effects of nonenzymatic glycosylation and fatty acids on tryptophan binding to human serum albumin 1992, 43:1829-1834.
133. Joseph K.S., Moser A.C., Basiaga S., Schiel J.E., Hage D.S. Evaluation of alternatives to warfarin as probes for Sudlow site I of human serum albumin: characterization by high-performance affinity chromatography. J Chromatogr A 2009, 1216:3492-3500.
134. Conrad M.L., Moser A.C., Hage D.S. Evaluation of indole-based probes for high-throughput screening of drug binding to human serum albumin: analysis by high-performance affinity chromatography. J Sep Sci 2009, 32:1145-1155.
135. Davis S.N. Goodman and Gilman's the pharmacological basis of therapeutics 2006, McGraw Hill, New York, [Ch. 60]. 11th ed. L.L. Brunton, J.S. Lazo, K.L. Parker (Eds.).
136. Hagstrom-Toft E., Hellstrom L., Moberg E. Lipolytic response during spontaneous hypoglycaemia in insulin-dependent diabetic subjects. Horm Metab Res 1998, 30:586-593.
137. Chase P.H., Glasgow A.M. Juvenile diabetes mellitus and serum lipids and lipoprotein levels. Am J Dis Child 1976, 130:1113-1117.
138. Bomba-Opon D., Wielgos M., Szymanska M., Bablok L. Effects of free fatty acids on the course of gestational diabetes mellitus. Neuroendocrinol Lett 2006, 27:277-280.
139. Spector A.A. Fatty acid binding to plasma albumin. J Lipid Res 1975, 16:165-179.
140. Noctor T.A.G., Wainer I.W., Hage D.S. Allosteric and competitive displacement of drugs from human serum albumin by octanoic acid, as revealed by high-performance liquid affinity chromatography, on a human serum albumin-based stationary phase. J Chromatogr 1992, 577:305-315.
141. Bhattacharya A.A., Grüne T., Curry S. Crystallographic analysis reveals common modes of binding of medium and long-chain fatty acids to human serum albumin. J Mol Biol 2000, 303:721-732.
142. Petitpas I., Grüne T., Bhattacharya A.A., Curry S. Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids. J Mol Biol 2000, 314:955-960.
143. Richieri G.V.S., Anel A., Kleinfeld A.M. Interactions of long-chain fatty acids and albumin: determination of free fatty acid levels using the fluorescent probe ADIFAB. Biochemistry 1993, 32:7574-7580.
144. Basiaga S.B., Hage D.S. Chromatographic studies of changes in binding of sulfonylurea drugs to human serum albumin due to glycation and fatty acids. J Chromatogr B 2010, 878:3193-3197.
145. Harrower A.D. Comparative tolerability of sulphonylureas in diabetes mellitus. Drug Saf 2000, 22:313-320.